RxDoctor Payments Data

Aravind Kumar, MD

Internal Medicine · West Melbourne, FLNPI 1871539072

Payments from drug & device makers

$1,547in general payments, 2019–2025

Across 18 payments — averaging $85.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$809
  • Amarin Pharma, Inc.$137
  • Boston Scientific$125
  • Harmony Biosciences LLC$125
  • Johnson & Johnson$120
  • Astellas Pharma US Inc$95
  • plus $137 from 6 others

What the payments were for

  • Travel & lodging$75849%
  • Food & beverage$66843%
  • Education$1228%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,547 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$459,974
Medicare patients
661
Services billed
5,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$167,422
MounjaroTirzepatide67$89,114
TradjentaLinagliptin154$73,189
OzempicSemaglutide58$70,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$53,578
JardianceEmpagliflozin112$39,265
XareltoRivaroxaban67$38,910
EntrestoSacubitril/Valsartan41$38,689
AptiomEslicarbazepine Acetate24$32,014
Breo ElliptaFluticasone/Vilanterol38$24,614
JanuviaSitagliptin Phosphate17$20,663
MyrbetriqMirabegron60$19,812
Tresiba Flextouch U-100Insulin Degludec31$17,719
Valsartan427$17,649
Spiriva RespimatTiotropium Bromide13$15,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Stiolto Respimat$15$133,990292 claims
Lilly USA, LLCMounjaro$36$89,11467 claims
Johnson & JohnsonXarelto$120$38,91067 claims
Astellas Pharma US IncMyrbetriq$95$19,81260 claims
AbbVieCreon, Vraylar$17$17,52823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in West Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →